© 1999 by European Society of Cardiology
The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation
aMedical College of Virginia Richmond, Virginia; bUniversity of Alabama at Birmingham Birmingham, Alabama, U.S.A.
The Ablate and Pace Trial (APT) was a prospective registry study of clinical outcomes and survival following ablation and pacing therapy for medically refractory atrial fibril-lation. One hundred and fifty-six patients were enrolled at 16 centres in North America. The mean patient age was 66±11 years, with mean left ventricular ejection fraction of 48%±18%. Seventy-eight percent of the patients had structural heart disease.
During one year of follow up, multiple measures of quality-of-life showed significant and sustained improvement following ablation and pacing therapy. Also, left ventricular ejection increased significantly for patients with baseline left ventricular ejection fraction <45%. Metabolic exercise testing showed trends toward improved exercise tolerance; however, these did not achieve statistical significance. The one year overall survival was 85%, with 3% of patients experiencing sudden death.
In summary, this large, non-randomized, trial showed significant improvement in quality of life and left ventricular function following ablation and pacing therapy. Ablation and pacing therapy is a viable strategy for palliative management of patients with medically refractory, highly symptomatic atrial fibrillation.
Key Words: Atrial fibrillation, radiofrequency ablation, quality of life, left ventricular function
Correspondence: Mark A. Wood, MD, Box 980053, Medical College of Virginia, Richmond, VA 23298, U.S.A.
[1] Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74: 242–246.[CrossRef][Web of Science][Medline]
[2] Fitzpatrick A, Kourouyan H, Siu A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499–507.[CrossRef][Web of Science][Medline]
[3] Jensen S, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. PACE 1995; 19: 1609–1614.
[4] Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol 78: 1431–1433.
[5] Kay GN, Ellenbogen K, Giudici M, et al. Survival in the APT trial: A prospective registry of AV nodal ablation and permanent pacemaker implantation for symptomatic atrial fibrillation. Circulation 1996; 94: A3985.
[6] Ellenbogen K, Kay GN, Giudici M, et al. Radiofrequency ablation of the AV junction improves functional status in patients with congestive heart failure: Results from the APT trial. Circulation 1996; 94: A3984.
[7] Redfield M, Kay GN, Jensen DN, Takle-Newhouse T, Giudici M, Ellenbogen K. Tachycardia related cardiomyopathy —a common and reversible cause of ventricular dysfunction in patients with atrial fibrillation. Circulation 1996; 94: A0118.
[8] Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Intervent Cardiol Electrophys 1998; 2: 121–135.
[9] Blackburn G, Harvey S, WilkoV BL. A chronotropic assessment exercise protocol to assess the need and efficacy of rate responsive pacing (Abstr). Med Sci Sports Exerc 1988; 20: S21.
[10] Ware JE. SF-36 health survey. Manual and interpretation guide 1993; Boston The Health Institute, New England Medical Center.
[11] Wicklund I, Gorkin K, Pawitan Y, et al. for the CAST Investigators. Methods for assessing quality of life in the Cardiac Arrhythmia Suppression Trial (CAST). Qual Life Res 1992; 1: 187–201.[CrossRef][Medline]
[12] Bubien RS, Knotts-Dolson SM, Plumb VJ, Kay GN. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation 1996; 94: 11585–11591.
[13] Heinz G, Siostrzoneh P, Kreiner G, et al. Improvement in left ventricular systolic function after successful radiofrequency His-bundle ablation for drug refractory chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol 1992; 69: 489–492.[CrossRef][Web of Science][Medline]
[14] Windecker S, Plumb VJ, Epstein AE, Kay GN. Does AV nodal ablation impair long-term survival compared to medical treatment of atrial fibrillation? J Am Cardiol 1994; 84: 1A.
[15] Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78: 1433–1436.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Stellbrink Heart rate, regularity, and synchronicity in heart failure: a tale of three brothers Eur. Heart J., April 1, 2005; 26(7): 637 - 638. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamada, D. O. Martin, K. A. Mowrey, N. L. Greenberg, and D. W. Wallick Effects of coupled pacing on cardiac performance during acute atrial tachycardia and fibrillation: an old therapy revisited for a new reason Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2630 - H2638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S K S Lairikyengbam, M H Anderson, and A G Davies Present treatment options for atrial fibrillation Postgrad. Med. J., February 1, 2003; 79(928): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berkowitsch, T. Neumann, K. Kurzidim, C. Reiner, M. Kuniss, G. Siemon, J. Sperzel, and H. F. Pitschner Comparison of generic health survey SF-36 and arrhythmia related symptom severity check list in relation to post-therapy AF recurrence Europace, January 1, 2003; 5(4): 351 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Capucci, G.Q. Villani, N. Marrazzo, and M. Piepoli The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P47 - P52. [Abstract] [PDF]
|
|
|
|
|
|
M. Brignole, M. Gammage, L. Jordaens, R. Sutton, and on behalf of the Barcelona Discussion Group Report of a study group on ablate and pace therapy for paroxysmal atrial fibrillation Europace, January 1, 1999; 1(1): 8 - 13. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||